semaglutide patent expiration us Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs Generic SEMAGLUTIDE INN equivalents, pharmaceutical

Published 25 May 2026 Reading time 16 minutes Last reviewed 25 May 2026 TRIUMPH-1 Phase 3 n = 2,339 "The largest weight loss ever observed for a non-surgical obesity treatment" 28.3% Average body weight loss (12 mg, 80 weeks) 30.3% Average weight loss (BMI 35 extension, 104 weeks) 45.3% Of 12 mg participants past the 30% threshold 24.1 cm Average waist circumference reduction at 12 mg The 30-second version What happened: On 21 May 2026, Eli Lilly published topline TRIUMPH-1 Phase 3 results for retatrutide

You Might Also Like

2020;371:m4147

Read the original article on NJ.com

Medically reviewed by Patricia Hartke, Pharm.D., BCPS Last update: April 22, 2026 Est

"GLP-1s can bolster motivation and self-efficacy, making habits easier to adopt, especially in connection with a digital behavior program built specifically for the GLP-1." "We originally built the GLP-1 Companion to mitigate lean mass lossa common side effect of GLP-1 therapy," continued Cook